<DOC>
	<DOC>NCT01387256</DOC>
	<brief_summary>This double blinded, placebo-controlled randomized trial will compare the safety, efficacy and acceptability of two medical abortion regimens up to 63 days since last Menstrual Period (LMP) in Tunisia and Vietnam. The first regimen will include a 200 mg oral dose of mifepristone followed by 800 mcg buccal misoprostol. The second regimen will include two 800 mcg doses of buccal misoprostol three hours apart. All drugs are administered AT home by the participant.</brief_summary>
	<brief_title>Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone</brief_title>
	<detailed_description />
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Gestational age &lt; 63 days since LMP, confirmed by ultrasound or clinical assessment. General good health including absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination. Agrees to return for followup visit and willing to provide an address and/or telephone number for purposes of followup. Able to consent to study participation. Gestational age &gt; 63 days LMP Confirmed or suspected ectopic or molar pregnancy Contraindications to medical abortion including intrauterine device (IUD) in place (must be removed before procedure), chronic adrenal failure, concurrent longterm corticosteroid therapy, history of allergy to mifepristone, misoprostol or prostaglandin, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyries.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>abortion</keyword>
	<keyword>mifepristone</keyword>
	<keyword>misoprostol</keyword>
	<keyword>with gestations &gt; 63 days LMP</keyword>
</DOC>